Rodrigo Fernandez-Valdivia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rodrigo Fernandez-Valdivia has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- May Chammaa
Department of Pathology, Wayne State University School of Medicine, Detroit, MI 48201, USA
3 shared publications Agnes Malysa
Department of Oncology Wayne State University School of Medicine Detroit Michigan
2 shared publicationsCarlos Redondo
Department of Pathology Wayne State University School of Medicine Detroit Michigan
2 shared publicationsGerold Bepler
Department of Oncology Wayne State University School of Medicine Detroit Michigan
2 shared publicationsHyejeong Jang
Biostatistics Core Barbara Ann Karmanos Cancer Institute Detroit Michigan
2 shared publications- Amnah Sharif
Department of Pathology, Wayne State University School of Medicine, Detroit, MI 48201, USA
1 shared publication
Latest Publications
- 22 April 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (6) , 1207-1209
Molecular deconstruction of anaplastic large cell Lymphoma (ALCL)
- 22 April 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (6) , 1207-1209
Molecular deconstruction of anaplastic large cell Lymphoma (ALCL)
- Open Access
- 8 August 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (16) , 5691
Notch Transduction in Non-Small Cell Lung Cancer
The evolutionarily-conserved Notch signaling pathway plays critical roles in cell communication, function and homeostasis equilibrium. The pathway serves as a cell-to-cell juxtaposed molecular transducer and is crucial in a number of cell processes including cell fate specification, asymmetric cell division and lateral inhibition. Notch also plays critical roles in organismal development, homeostasis, and regeneration, including somitogenesis, left-right asymmetry, neurogenesis, tissue repair, self-renewal and stemness, and its dysregulation has causative roles in a number of congenital and acquired pathologies, including cancer. In the lung, Notch activity is necessary for cell fate specification and expansion, and its aberrant activity is markedly linked to various defects in club cell formation, alveologenesis, and non-small cell lung cancer (NSCLC) development. In this review, we focus on the role this intercellular signaling device plays during lung development and on its functional relevance in proximo-distal cell fate specification, branching morphogenesis, and alveolar cell determination and maturation, then revise its involvement in NSCLC formation, progression and treatment refractoriness, particularly in the context of various mutational statuses associated with NSCLC, and, lastly, conclude by providing a succinct outlook of the therapeutic perspectives of Notch targeting in NSCLC therapy, including an overview on prospective synthetic lethality approaches.
- 8 August 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (16) , 5691
Open AccessNotch Transduction in Non-Small Cell Lung Cancer
The evolutionarily-conserved Notch signaling pathway plays critical roles in cell communication, function and homeostasis equilibrium. The pathway serves as a cell-to-cell juxtaposed molecular transducer and is crucial in a number of cell processes including cell fate specification, asymmetric cell division and lateral inhibition. Notch also plays critical roles in organismal development, homeostasis, and regeneration, including somitogenesis, left-right asymmetry, neurogenesis, tissue repair, self-renewal and stemness, and its dysregulation has causative roles in a number of congenital and acquired pathologies, including cancer. In the lung, Notch activity is necessary for cell fate specification and expansion, and its aberrant activity is markedly linked to various defects in club cell formation, alveologenesis, and non-small cell lung cancer (NSCLC) development. In this review, we focus on the role this intercellular signaling device plays during lung development and on its functional relevance in proximo-distal cell fate specification, branching morphogenesis, and alveolar cell determination and maturation, then revise its involvement in NSCLC formation, progression and treatment refractoriness, particularly in the context of various mutational statuses associated with NSCLC, and, lastly, conclude by providing a succinct outlook of the therapeutic perspectives of Notch targeting in NSCLC therapy, including an overview on prospective synthetic lethality approaches.
- 1 January 2019
- Vol. 40 (4) , 184-194
Expression of Notch Receptors and Ligands in the Coccygeal Body
BACKGROUND: The recent discovery of neural stem cells in the sacrococcygeal end of the filum terminale, the presence of remnants of the most powerful totipotent stem cell generators and inductors, the primitive streak and node, the existence of the unique non-mutator sacrococcygeal teratomas, and the recent disclosing of neuroimmunomodulatory and hematopoietic roles of Luschka's body, indicate that the sacrococcygeal region is a distinctive anatomic environment rich in stem cells and instructive signals, and that the coccygeal body may constitute a more complex entity than a mere caudal, vascularly-derived glomic anastomosis. Ascribed as an arterial-venous shunt located at the tip of the coccyx and analog to the glomera caudalia in other vertebrates, the glomus coccygeum has recently revealed a complex organ with peculiar 3D topology, broad innervation, catecholamine-synthesizing activity, and neutrophil-formation and lymphopoietic-regulating properties. METHODS: In the present research work, we sought to start exploring the potential cell-functional roles of the glomus coccygeum by conducting a methodical assessment of the expression of Notch pathway receptors and ligands in the human Luschka's body. RESULTS: Our data indicates that Notch receptors are dynamically and distinctively expressed in the coccygeal body and that Notch ligands are markedly differentially expressed in newborn and adult coccygeal glomi. CONCLUSIONS: Our observations suggest that Notch signaling may have relevant roles in glomus coccygeum function and biology.
- 1 January 2019
- Vol. 40 (4) , 184-194
Expression of Notch Receptors and Ligands in the Coccygeal Body
BACKGROUND: The recent discovery of neural stem cells in the sacrococcygeal end of the filum terminale, the presence of remnants of the most powerful totipotent stem cell generators and inductors, the primitive streak and node, the existence of the unique non-mutator sacrococcygeal teratomas, and the recent disclosing of neuroimmunomodulatory and hematopoietic roles of Luschka's body, indicate that the sacrococcygeal region is a distinctive anatomic environment rich in stem cells and instructive signals, and that the coccygeal body may constitute a more complex entity than a mere caudal, vascularly-derived glomic anastomosis. Ascribed as an arterial-venous shunt located at the tip of the coccyx and analog to the glomera caudalia in other vertebrates, the glomus coccygeum has recently revealed a complex organ with peculiar 3D topology, broad innervation, catecholamine-synthesizing activity, and neutrophil-formation and lymphopoietic-regulating properties. METHODS: In the present research work, we sought to start exploring the potential cell-functional roles of the glomus coccygeum by conducting a methodical assessment of the expression of Notch pathway receptors and ligands in the human Luschka's body. RESULTS: Our data indicates that Notch receptors are dynamically and distinctively expressed in the coccygeal body and that Notch ligands are markedly differentially expressed in newborn and adult coccygeal glomi. CONCLUSIONS: Our observations suggest that Notch signaling may have relevant roles in glomus coccygeum function and biology.
- Open Access
- 12 October 2018
- Published by Wiley in Journal of Cellular Physiology
- Vol. 233 (12)
Cover Image, Volume 233, Number 12, December 2018
- 12 October 2018
- Published by Wiley in Journal of Cellular Physiology
- Vol. 233 (12)
Open AccessCover Image, Volume 233, Number 12, December 2018
- 28 June 2018
- Published by Wiley in Journal of Cellular Physiology
- Vol. 233 (12) , 9548-9562
RUMI is a novel negative prognostic marker and therapeutic target in non–small‐cell lung cancer
Recent comprehensive next‐generation genome and transcriptome analyses in lung cancer patients, several clinical observations, and compelling evidence from mouse models of lung cancer have uncovered a critical role for Notch signaling in the initiation and progression of non–small‐cell lung cancer (NSCLC). Notably, Rumi is a “protein O‐glucosyltransferase” that regulates Notch signaling through O‐glucosylation of Notch receptors, and is the only enzymatic regulator whose activity is required for both ligand‐dependent and ligand‐independent activation of Notch. We have conducted a detailed study on RUMI’s involvement in NSCLC development and progression, and have further explored the therapeutic potential of its targeting in NSCLC. We have determined that Rumi is highly expressed in the alveolar and bronchiolar epithelia, including club cells and alveolar type II cells. Remarkably, RUMI maps to the region of chromosome 3q that corresponds to the major signature of neoplastic transformation in NSCLC, and is markedly amplified and overexpressed in NSCLC tumors. Notably, RUMI expression levels are predictive of poor prognosis and survival in NSCLC patients. Our data indicates that RUMI modulates Notch activity in NSCLC cells, and that its silencing dramatically decreases cell proliferation, migration, and survival. RUMI downregulation causes severe cell cycle S‐phase arrest, increases genome instability, and induces late apoptotic–nonapoptotic cell death. Our studies demonstrate that RUMI is a novel negative prognostic factor with significant therapeutic potential in NSCLC, which embodies particular relevance especially when considering that, while current Notch inhibitory strategies target only ligand‐dependent Notch activation, a large number of NSCLCs are driven by ligand‐independent Notch activity.
- 28 June 2018
- Published by Wiley in Journal of Cellular Physiology
- Vol. 233 (12) , 9548-9562
RUMI is a novel negative prognostic marker and therapeutic target in non–small‐cell lung cancer
Recent comprehensive next‐generation genome and transcriptome analyses in lung cancer patients, several clinical observations, and compelling evidence from mouse models of lung cancer have uncovered a critical role for Notch signaling in the initiation and progression of non–small‐cell lung cancer (NSCLC). Notably, Rumi is a “protein O‐glucosyltransferase” that regulates Notch signaling through O‐glucosylation of Notch receptors, and is the only enzymatic regulator whose activity is required for both ligand‐dependent and ligand‐independent activation of Notch. We have conducted a detailed study on RUMI’s involvement in NSCLC development and progression, and have further explored the therapeutic potential of its targeting in NSCLC. We have determined that Rumi is highly expressed in the alveolar and bronchiolar epithelia, including club cells and alveolar type II cells. Remarkably, RUMI maps to the region of chromosome 3q that corresponds to the major signature of neoplastic transformation in NSCLC, and is markedly amplified and overexpressed in NSCLC tumors. Notably, RUMI expression levels are predictive of poor prognosis and survival in NSCLC patients. Our data indicates that RUMI modulates Notch activity in NSCLC cells, and that its silencing dramatically decreases cell proliferation, migration, and survival. RUMI downregulation causes severe cell cycle S‐phase arrest, increases genome instability, and induces late apoptotic–nonapoptotic cell death. Our studies demonstrate that RUMI is a novel negative prognostic factor with significant therapeutic potential in NSCLC, which embodies particular relevance especially when considering that, while current Notch inhibitory strategies target only ligand‐dependent Notch activation, a large number of NSCLCs are driven by ligand‐independent Notch activity.